phase III clinical study
Novartis, SOLTI Collaborate on HARMONIA Head-to-Head Breast Cancer Trial of Kisqali Versus Ibrance
The Phase III trial will use RNA-based subtyping to assess if Kisqali alters tumor biology and allows HR-positive, HER2-negative advanced breast cancer patients to benefit from it.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
CHMP Recommends Merck's Keytruda Plus Chemo for PD-L1-Positve TNBC
The committee recommended the combo for PD-L1-positive advanced cancers based on data from the Phase III KEYNOTE-355 trial.
IO Biotech Studying Cancer Vaccine With Merck's Keytruda in Advanced Melanoma Patients
The company will study the activity of IO102-IO103 with Merck's anti-PD-1 drug in advanced melanoma patients and look for biomarkers of response.
AstraZeneca, Hutchmed Launch Phase III Randomized Trial of Orpathys, Tagrisso in China
The study will randomize more than 300 advanced EGFR-mutated NSCLC patients with MET overexpression to the combination or just Tagrisso.